Back

Silexion starts global Phase 2/3 trial of SIL204 in pancreatic cancer

Verifying
  • Silexion dosed the first patient in its global Phase 2/3 SIL204 pancreatic cancer trial.
  • Approximately 18 patients comprise the safety run-in, followed by approximately 166 randomized participants.
  • Tel Aviv Sourasky Medical Center is the trial's anchor clinical center in Israel.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Silexion starts global Phase 2/3 trial of SIL204 in pancreatic cancer - CoinPost Terminal